However, no significant increase in the risk of serious biliary tract disease has been observed
As a triple agonist targeting GLP-1, GIP, and glucagon receptors, it provides a unique framework for studying multi-receptor metabolic modulation
More than half of Americans taking GLP-1s say it was difficult to afford
Retatrutide differs from Tirzepatide and Semaglutide because it is designed to activate three metabolic receptor pathways GLP-1, GIP, and glucagon receptors
Starting at a lower retatrutide dose and increasing every four weeks gives GI adaptation time to occur as glucagon receptor tone adjusts, reducing nausea, vomiting, and diarrhea during induction
For a broader view of peptide options, see our best peptides for weight loss guide